First identified as a fusion partner of retinoic acid receptor alpha (RAR) in acute promyelocytic leukemia (APL) in cases with a t(11; 17) translocation [3], PLZF is now generally described as a transcriptional repressor and, more precisely, an epigenetic regulator. Here, ZBTB16 is linked to acute promyelocytic leukemia.